Literature DB >> 23621126

Aberrant microRNAs expression patterns in pancreatic cancer and their clinical translation.

Yiqi Du1, Minghao Liu, Jun Gao, Zhaoshen Li.   

Abstract

Pancreatic cancer (PC) has a high rate of mortality and a poorly understood mechanism of progression. MicroRNA (miRNA) molecules have been proved to play an important role in malignant transformation and cancer development. Thousands of miRNAs have been screened in PC and several of them, such as miR-21, 155, and 196a, show up- or down-regulation that is associated with progression of the disease. However, the roles of these molecules in the regulation of tumorigenesis are not clear. Some studies have investigated whether circulating miRNAs could be detected in serum of patients with PC and whether expression levels of specific miRNAs differed between PC patients, pancreatitis patients, and healthy individuals. The current review focuses on this topic along with a possible role for miRNAs in the early diagnosis of PC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23621126     DOI: 10.1089/cbr.2012.1389

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  11 in total

1.  The microRNA-375 as a potentially promising biomarker to predict the prognosis of patients with head and neck or esophageal squamous cell carcinoma: a meta-analysis.

Authors:  Peng Wang; LiangLiang Xu; Lian Li; ShengSheng Ren; JianWei Tang; Ming Zhang; MingQing Xu
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-02-12       Impact factor: 2.503

2.  Effects of preanalytic variables on circulating microRNAs in whole blood.

Authors:  Hua Zhao; Jie Shen; Qiang Hu; Warren Davis; Leonardo Medico; Dan Wang; Li Yan; Yuqing Guo; Biao Liu; Maochun Qin; Mary Nesline; Qianqian Zhu; Song Yao; Christine B Ambrosone; Song Liu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-12       Impact factor: 4.254

Review 3.  Identification of circulating MicroRNAs as novel potential biomarkers for hepatocellular carcinoma detection: a systematic review and meta-analysis.

Authors:  G Li; Q Shen; C Li; D Li; J Chen; M He
Journal:  Clin Transl Oncol       Date:  2015-05-09       Impact factor: 3.405

Review 4.  Targeting miRNAs for pancreatic cancer therapy.

Authors:  Min Shi; Dacheng Xie; Yong Gaod; Keping Xie
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

5.  From moderately severe to severe hypertriglyceridemia induced acute pancreatitis: circulating miRNAs play role as potential biomarkers.

Authors:  Fangmei An; Qiang Zhan; Min Xia; Lisha Jiang; Guoming Lu; Mindan Huang; Jizhong Guo; Side Liu
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

Review 6.  Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.

Authors:  Ingrid Garajová; Tessa Y Le Large; Adam E Frampton; Christian Rolfo; Johannes Voortman; Elisa Giovannetti
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411

Review 7.  Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects.

Authors:  Avineesh Singh; Vijay K Patel; Deepak K Jain; Preeti Patel; Harish Rajak
Journal:  Oncol Ther       Date:  2016-06-10

8.  miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database.

Authors:  Hsi-Yuan Huang; Yang-Chi-Dung Lin; Jing Li; Kai-Yao Huang; Sirjana Shrestha; Hsiao-Chin Hong; Yun Tang; Yi-Gang Chen; Chen-Nan Jin; Yuan Yu; Jia-Tong Xu; Yue-Ming Li; Xiao-Xuan Cai; Zhen-Yu Zhou; Xiao-Hang Chen; Yuan-Yuan Pei; Liang Hu; Jin-Jiang Su; Shi-Dong Cui; Fei Wang; Yue-Yang Xie; Si-Yuan Ding; Meng-Fan Luo; Chih-Hung Chou; Nai-Wen Chang; Kai-Wen Chen; Yu-Hsiang Cheng; Xin-Hong Wan; Wen-Lian Hsu; Tzong-Yi Lee; Feng-Xiang Wei; Hsien-Da Huang
Journal:  Nucleic Acids Res       Date:  2020-01-08       Impact factor: 16.971

Review 9.  Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance.

Authors:  Ming-Zhe Ma; Xiang Kong; Ming-Zhe Weng; Kun Cheng; Wei Gong; Zhi-Wei Quan; Cheng-Hong Peng
Journal:  J Exp Clin Cancer Res       Date:  2013-09-28

Review 10.  Aberrant MicroRNAs in Pancreatic Cancer: Researches and Clinical Implications.

Authors:  Tao Sun; Xiangyu Kong; Yiqi Du; Zhaoshen Li
Journal:  Gastroenterol Res Pract       Date:  2014-05-08       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.